Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma.

ABSTRACT:

Background

Despite therapeutic advances in targeted therapy, metastatic renal cell carcinoma (RCC) remains incurable for the vast majority of patients. Key molecular events in the pathogenesis of RCC include inactivation of the VHL tumour suppressor gene (TSG), inactivation of chromosome 3p TSGs implicated in chromatin modification and remodelling and de novo tumour-specific promoter methylation of renal TSGs. In the light of these observations it can be proposed that, as in some haematological malignancies, demethylating agents such as azacitidine might be beneficial for the treatment of advanced RCC.

Results

Here we report that the treatment of RCC cell lines with azacitidine suppressed cell proliferation in all 15 lines tested. A marked response to azacitidine therapy (>5

SUBMITTER: Ricketts CJ 

PROVIDER: S-EPMC3848591 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature